179 related articles for article (PubMed ID: 34643211)
1. VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma.
Broijl A; de Jong ACM; van Duin M; Sonneveld P; Kühnau J; van der Velden VHJ
Am J Clin Pathol; 2022 Apr; 157(4):494-497. PubMed ID: 34643211
[TBL] [Abstract][Full Text] [Related]
2. VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months.
Courville EL; Yohe S; Shivers P; Linden MA
Am J Clin Pathol; 2020 Jan; 153(2):221-228. PubMed ID: 31679012
[TBL] [Abstract][Full Text] [Related]
3. Camelid-derived CD38 antibody successfully circumvents epitope blockade by the therapeutic anti-CD38 antibody daratumumab.
ElMaraashly AH; Tario J; Hillengass J; Qian YW
Am J Clin Pathol; 2023 Nov; 160(5):524-532. PubMed ID: 37527544
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry.
Sato K; Okazuka K; Ishida T; Sakamoto J; Kaneko S; Nashimoto J; Uto Y; Ogura M; Yoshiki Y; Abe Y; Maeda A; Hamazaki H; Tsukada N; Hiragohri Y; Suzuki K
Ann Hematol; 2021 Dec; 100(12):2989-2995. PubMed ID: 34430990
[TBL] [Abstract][Full Text] [Related]
5. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
[No Abstract] [Full Text] [Related]
6. Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry.
Takamatsu H; Yoroidaka T; Fujisawa M; Kobori K; Hanawa M; Yamashita T; Murata R; Ueda M; Nakao S; Matsue K
Int J Hematol; 2019 Apr; 109(4):377-381. PubMed ID: 30778767
[TBL] [Abstract][Full Text] [Related]
7. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
Adams HC; Stevenaert F; Krejcik J; Van der Borght K; Smets T; Bald J; Abraham Y; Ceulemans H; Chiu C; Vanhoof G; Usmani SZ; Plesner T; Lonial S; Nijhof I; Lokhorst HM; Mutis T; van de Donk NWCJ; Sasser AK; Casneuf T
Cytometry A; 2019 Mar; 95(3):279-289. PubMed ID: 30536810
[TBL] [Abstract][Full Text] [Related]
8. Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods.
Yoroidaka T; Narita K; Takamatsu H; Fujisawa M; Nakao S; Matsue K
Sci Rep; 2021 May; 11(1):11218. PubMed ID: 34045494
[TBL] [Abstract][Full Text] [Related]
9. Artifactual Kappa Light Chain Restriction of Marrow Hematogones: A Potential Diagnostic Pitfall in Minimal Residual Disease Assessment of Plasma Cell Myeloma Patients on Daratumumab.
Jiang XY; Luider J; Shameli A
Cytometry B Clin Cytom; 2020 Jan; 98(1):68-74. PubMed ID: 31313879
[TBL] [Abstract][Full Text] [Related]
10. Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma.
Steinhardt MJ; Zhou X; Krummenast F; Meckel K; Nickel K; Böckle D; Messerschmidt J; Knorz S; Dierks A; Heidemeier A; Lapa C; Einsele H; Rasche L; Kortüm KM
Int J Immunopathol Pharmacol; 2020; 34():2058738420980258. PubMed ID: 33353443
[TBL] [Abstract][Full Text] [Related]
11. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
[TBL] [Abstract][Full Text] [Related]
12. CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab.
Soh KT; Tario JD; Hahn T; Hillengass J; McCarthy PL; Wallace PK
Cytometry B Clin Cytom; 2021 Jul; 100(4):497-508. PubMed ID: 33017079
[TBL] [Abstract][Full Text] [Related]
13. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
Krejcik J; Casneuf T; Nijhof IS; Verbist B; Bald J; Plesner T; Syed K; Liu K; van de Donk NW; Weiss BM; Ahmadi T; Lokhorst HM; Mutis T; Sasser AK
Blood; 2016 Jul; 128(3):384-94. PubMed ID: 27222480
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometric myeloma measurable residual disease testing in the era of targeted therapies.
Ng DP
Int J Lab Hematol; 2021 Jul; 43 Suppl 1():71-77. PubMed ID: 34288444
[TBL] [Abstract][Full Text] [Related]
15. VS38 as a promising CD38 substitute antibody for flow cytometric detection of plasma cells in the daratumumab era.
Mizuta S; Kawata T; Kawabata H; Yamane N; Mononobe S; Komai T; Koba Y; Ukyo N; Tamekane A; Watanabe M
Int J Hematol; 2019 Sep; 110(3):322-330. PubMed ID: 31183814
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma.
Lee HT; Kim Y; Park UB; Jeong TJ; Lee SH; Heo YS
Biochem Biophys Res Commun; 2021 Jan; 536():26-31. PubMed ID: 33360095
[TBL] [Abstract][Full Text] [Related]
17. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.
Schriewer L; Schütze K; Petry K; Hambach J; Fumey W; Koenigsdorf J; Baum N; Menzel S; Rissiek B; Riecken K; Fehse B; Röckendorf JL; Schmid J; Albrecht B; Pinnschmidt H; Ayuk F; Kröger N; Binder M; Schuch G; Hansen T; Haag F; Adam G; Koch-Nolte F; Bannas P
Theranostics; 2020; 10(6):2645-2658. PubMed ID: 32194826
[No Abstract] [Full Text] [Related]
18. Limitations of VS38c labeling in the detection of plasma cell myeloma by flow cytometry.
Czeti Á; Szalóki G; Varga G; Szita VR; Komlósi ZI; Takács F; Márk Á; Timár B; Matolcsy A; Barna G
Cytometry A; 2022 Feb; 101(2):159-166. PubMed ID: 34296508
[TBL] [Abstract][Full Text] [Related]
19. Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach.
Alici E; Chrobok M; Lund J; Ahmadi T; Khan I; Duru AD; Nahi H
Br J Haematol; 2016 Aug; 174(3):473-7. PubMed ID: 26455823
[No Abstract] [Full Text] [Related]
20. Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy.
Mathis S; Chapuis N; Borgeot J; Maynadié M; Fontenay M; Béné MC; Guy J; Bardet V
Cytometry B Clin Cytom; 2015 Mar; 88(2):101-9. PubMed ID: 25399680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
